{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:20:26Z","timestamp":1754151626916,"version":"3.41.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2021-1060"],"award-info":[{"award-number":["075-15-2021-1060"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017638","name":"Ministry of Health of the Russian Federation","doi-asserted-by":"publisher","award":["123021500076-3"],"award-info":[{"award-number":["123021500076-3"]}],"id":[{"id":"10.13039\/501100017638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11845-025-03917-4","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T15:59:17Z","timestamp":1742659157000},"page":"817-825","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of progesterone receptor expression in non-small cell lung cancer tissue"],"prefix":"10.1007","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-1153","authenticated-orcid":false,"given":"Romanov","family":"I.P.","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7673-4284","authenticated-orcid":false,"given":"Bogush","family":"T.A.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2974-9555","authenticated-orcid":false,"given":"Scherbakov","family":"A.M.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-9222","authenticated-orcid":false,"given":"Grishanina","family":"A.N.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-3669","authenticated-orcid":false,"given":"Bogush","family":"E.A.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5969-0219","authenticated-orcid":false,"given":"Ravcheeva","family":"A.B.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8462-2178","authenticated-orcid":false,"given":"Kosorukov","family":"V.S.","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"14","key":"3917_CR1","doi-asserted-by":"publisher","first-page":"6450","DOI":"10.1158\/0008-5472.can-04-3087","volume":"65","author":"H Ishibashi","year":"2005","unstructured":"Ishibashi H, Suzuki T, Suzuki S and others (2005) Progesterone receptor in non-small cell lung cancer\u2013a potent prognostic factor and possible target for endocrine therapy. Cancer Res 65(14):6450\u20136458. https:\/\/doi.org\/10.1158\/0008-5472.can-04-3087","journal-title":"Cancer Res"},{"issue":"9","key":"3917_CR2","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.steroids.2011.04.015","volume":"76","author":"DC Marquez-Garban","year":"2011","unstructured":"Marquez-Garban DC, Mah V, Alavi M and others (2011) Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. Steroids 76(9):910\u2013920. https:\/\/doi.org\/10.1016\/j.steroids.2011.04.015","journal-title":"Steroids"},{"issue":"1\u20132","key":"3917_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.37489\/0235-2990-2024-69-1-2-29-36","volume":"69","author":"IP Romanov","year":"2024","unstructured":"Romanov IP, Bogush TA, Scherbakov AM and others (2024) Molecular characteristics of non-small cell lung cancer tissue based on quantitative indicators of progesterone receptors expression. Antibiot Khimioter Antibiot Chemother 69(1\u20132):29\u201336. https:\/\/doi.org\/10.37489\/0235-2990-2024-69-1-2-29-36. (In Russ.)","journal-title":"Antibiot Khimioter Antibiot Chemother"},{"issue":"1","key":"3917_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2010.09.008","volume":"300","author":"N Ahmad","year":"2011","unstructured":"Ahmad N, Kumar R (2011) Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett 300(1):1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2010.09.008","journal-title":"Cancer Lett"},{"issue":"3","key":"3917_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.3892\/or.18.3.685","volume":"18","author":"Y Nishizawa","year":"2007","unstructured":"Nishizawa Y, Yamasaki M, Katayama H and others (2007) Establishment of a progesterone-sensitive cell line from human lung cancer. Oncol Rep 18(3):685\u2013690. https:\/\/doi.org\/10.3892\/or.18.3.685","journal-title":"Oncol Rep"},{"key":"3917_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12935-018-0683-z","volume":"18","author":"HE Kapperman","year":"2018","unstructured":"Kapperman HE, Goyeneche AA, Telleria CM (2018) Mifepristone inhibits non-small cell lung carcinoma cellular escape from DNA damaging cisplatin. Cancer Cell Int 18:185. https:\/\/doi.org\/10.1186\/s12935-018-0683-z","journal-title":"Cancer Cell Int"},{"key":"3917_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.biopha.2017.03.091","volume":"90","author":"G Zheng","year":"2017","unstructured":"Zheng G, Shen Z, Chen H and others (2017) Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS\/RAF\/MEK\/MAPK signaling pathway. Biomed Pharmacother 90:437\u2013445. https:\/\/doi.org\/10.1016\/j.biopha.2017.03.091","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3917_CR8","first-page":"119","volume":"30","author":"JH Check","year":"2010","unstructured":"Check JH, Sansoucie L, Chern J and others (2010) Mifepristone treatment improves length and quality of survival of mice with spontaneous lung cancer. Anticancer Res 30(1):119\u2013122","journal-title":"Anticancer Res"},{"issue":"50","key":"3917_CR9","doi-asserted-by":"publisher","first-page":"82648","DOI":"10.18632\/oncotarget.12244","volume":"7","author":"R Berardi","year":"2016","unstructured":"Berardi R, Morgese F, Santinelli A and others (2016) Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget 7(50):82648\u201382657. https:\/\/doi.org\/10.18632\/oncotarget.12244","journal-title":"Oncotarget"},{"issue":"17","key":"3917_CR10","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1158\/1078-0432.ccr-09-0033","volume":"15","author":"MG Raso","year":"2009","unstructured":"Raso MG, Behrens C, Herynk MH and others (2009) Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 15(17):5359\u20135368. https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-0033","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3917_CR11","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/1078-0432.ccr-10-0992","volume":"17","author":"LP Stabile","year":"2011","unstructured":"Stabile LP, Dacic S, Land SR and others (2011) Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome. Clin Cancer Res 17(1):154\u2013164. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-0992","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3917_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/cncr.26282","volume":"118","author":"D Rades","year":"2012","unstructured":"Rades D, Setter C, Dahl O and others (2012) The prognostic impact of tumor cell expression of estrogen receptor-\u03b1, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer. Cancer 118(1):157\u2013163. https:\/\/doi.org\/10.1002\/cncr.26282","journal-title":"Cancer"},{"key":"3917_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.steroids.2015.01.020","volume":"98","author":"K Skjefstad","year":"2015","unstructured":"Skjefstad K, Richardsen E, Donnem T and others (2015) The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: gender-related impacts and correlation with disease-specific survival. Steroids 98:29\u201336. https:\/\/doi.org\/10.1016\/j.steroids.2015.01.020","journal-title":"Steroids"},{"key":"3917_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2020.09.031","volume":"141","author":"K Rosen","year":"2020","unstructured":"Rosen K, Prasad V, Chen EY (2020) Censored patients in Kaplan-Meier plots of cancer drugs: an empirical analysis of data sharing. Eur J Cancer 141:152\u2013161. https:\/\/doi.org\/10.1016\/j.ejca.2020.09.031","journal-title":"Eur J Cancer"},{"key":"3917_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jclinepi.2021.07.013","volume":"139","author":"T Olivier","year":"2021","unstructured":"Olivier T, Haslam A, Prasad V (2021) Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. J Clin Epidemiol 139:80\u201386. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.07.013","journal-title":"J Clin Epidemiol"},{"key":"3917_CR16","doi-asserted-by":"publisher","unstructured":"Olivier T, Haslam A, Prasad V (2024) Health-related quality of life in trials with high rates of early censoring: caution advised. Eur J Cancer 205:114105. https:\/\/doi.org\/10.1016\/j.ejca.2024.114105","DOI":"10.1016\/j.ejca.2024.114105"},{"key":"3917_CR17","doi-asserted-by":"publisher","first-page":"114047","DOI":"10.1016\/j.ejca.2024.114047","volume":"204","author":"E Lenglin\u00e9","year":"2024","unstructured":"Lenglin\u00e9 E, Baba J, de Boissieu P and others (2024) Composite event-free-survival as an endpoint in oncology drug evaluation: review and guidance perspectives from the Haute Autorit\u00e9 de Sant\u00e9 (HAS). Eur J Cancer 204:114047. https:\/\/doi.org\/10.1016\/j.ejca.2024.114047","journal-title":"Eur J Cancer"},{"key":"3917_CR18","doi-asserted-by":"publisher","first-page":"114022","DOI":"10.1016\/j.ejca.2024.114022","volume":"202","author":"V Lesan","year":"2024","unstructured":"Lesan V, Olivier T, Prasad V (2024) Progression-free survival estimates are shaped by specific censoring rules: implications for PFS as an endpoint in cancer randomized trials. Eur J Cancer 202:114022. https:\/\/doi.org\/10.1016\/j.ejca.2024.114022","journal-title":"Eur J Cancer"},{"key":"3917_CR19","doi-asserted-by":"publisher","first-page":"113942","DOI":"10.1016\/j.ejca.2024.113942","volume":"201","author":"T Olivier","year":"2024","unstructured":"Olivier T, Prasad V (2024) Equal censoring but still informative: when the reasons for censoring differ between treatment arms. Eur J Cancer 201:113942. https:\/\/doi.org\/10.1016\/j.ejca.2024.113942","journal-title":"Eur J Cancer"},{"issue":"4","key":"3917_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2144\/btn-2020-0024","volume":"69","author":"TA Bogush","year":"2020","unstructured":"Bogush TA, Basharina AA, Eliseeva BK and others (2020) A new approach to epithelial-mesenchymal transition diagnostics in epithelial tumors: double immunofluorescent staining and flow cytometry. Biotechniques 69(4):257\u2013263. https:\/\/doi.org\/10.2144\/btn-2020-0024","journal-title":"Biotechniques"},{"issue":"9318","key":"3917_CR21","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/s0140-6736(02)08594-x","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG (2002) Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359(9318):1686\u20131689. https:\/\/doi.org\/10.1016\/s0140-6736(02)08594-x","journal-title":"Lancet"},{"issue":"2","key":"3917_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.11613\/bm.2012.018","volume":"22","author":"M Lucijanic","year":"2012","unstructured":"Lucijanic M, Petrovecki M (2012) Analysis of censored data. Biochem Med (Zagreb) 22(2):151\u2013155. https:\/\/doi.org\/10.11613\/bm.2012.018","journal-title":"Biochem Med (Zagreb)"},{"issue":"1","key":"3917_CR23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4103\/2229-3485.92307","volume":"3","author":"P Ranganathan","year":"2012","unstructured":"Ranganathan P, Pramesh CS (2012) Censoring in survival analysis: potential for bias. Perspect Clin Res 3(1):40. https:\/\/doi.org\/10.4103\/2229-3485.92307","journal-title":"Perspect Clin Res"},{"issue":"50","key":"3917_CR24","doi-asserted-by":"publisher","first-page":"e9204","DOI":"10.1097\/md.0000000000009204","volume":"96","author":"X Zhu","year":"2017","unstructured":"Zhu X, Zhou X, Zhang Y and others (2017) Reporting and methodological quality of survival analysis in articles published in Chinese oncology journals. Medicine (Baltimore) 96(50):e9204. https:\/\/doi.org\/10.1097\/md.0000000000009204","journal-title":"Medicine (Baltimore)"},{"key":"3917_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev.publhealth.18.1.83","volume":"18","author":"KM Leung","year":"1997","unstructured":"Leung KM, Elashoff RM, Afifi AA (1997) Censoring issues in survival analysis. Annu Rev Public Health 18:83\u2013104. https:\/\/doi.org\/10.1146\/annurev.publhealth.18.1.83","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"3917_CR26","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/ERC-20-0335","volume":"28","author":"VC Jordan","year":"2021","unstructured":"Jordan VC (2021) 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened? Endocr Relat Cancer 28(1):R11-r30. https:\/\/doi.org\/10.1530\/ERC-20-0335","journal-title":"Endocr Relat Cancer"},{"key":"3917_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3389\/fphar.2017.00620","volume":"8","author":"VM Quirke","year":"2017","unstructured":"Quirke VM (2017) Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: a case-study in pharmaceutical innovation. Front Pharmacol 8:620. https:\/\/doi.org\/10.3389\/fphar.2017.00620","journal-title":"Front Pharmacol"},{"issue":"1","key":"3917_CR28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/BF03168937","volume":"171","author":"SB Hooper","year":"2002","unstructured":"Hooper SB, Hill AD, Kennedy S and others (2002) Tamoxifen as the primary treatment in elderly patients with breast cancer. Ir J Med Sci 171(1):28\u201330. https:\/\/doi.org\/10.1007\/BF03168937","journal-title":"Ir J Med Sci"},{"issue":"1","key":"3917_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/BF03168929","volume":"171","author":"MJ Kennedy","year":"2002","unstructured":"Kennedy MJ (2002) The limits of tamoxifen. Ir J Med Sci 171(1):8\u20139. https:\/\/doi.org\/10.1007\/BF03168929","journal-title":"Ir J Med Sci"},{"issue":"1\u20133","key":"3917_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/0022-4731(87)90345-1","volume":"27","author":"VC Jordan","year":"1987","unstructured":"Jordan VC, Fritz NF, Gottardis MM (1987) Strategies for breast cancer therapy with antiestrogens. J Steroid Biochem 27(1\u20133):493\u2013498. https:\/\/doi.org\/10.1016\/0022-4731(87)90345-1","journal-title":"J Steroid Biochem"},{"issue":"3","key":"3917_CR31","doi-asserted-by":"publisher","first-page":"R235","DOI":"10.1530\/ERC-14-0092","volume":"21","author":"VC Jordan","year":"2014","unstructured":"Jordan VC (2014) Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer 21(3):R235\u2013R246. https:\/\/doi.org\/10.1530\/ERC-14-0092","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"3917_CR32","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1134\/s0006297910120011","volume":"75","author":"TA Bogush","year":"2010","unstructured":"Bogush TA, Dudko EA, Beme AA and others (2010) Estrogen receptors, antiestrogens, and non-small cell lung cancer. Biochemistry (Mosc) 75(12):1421\u20131427. https:\/\/doi.org\/10.1134\/s0006297910120011","journal-title":"Biochemistry (Mosc)"},{"issue":"8","key":"3917_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3390\/ijms18081713","volume":"18","author":"LH Hsu","year":"2017","unstructured":"Hsu LH, Chu NM, Kao SH (2017) Estrogen, estrogen receptor and lung cancer. Int J Mol Sci 18(8):1713. https:\/\/doi.org\/10.3390\/ijms18081713","journal-title":"Int J Mol Sci"},{"key":"3917_CR34","doi-asserted-by":"publisher","first-page":"600121","DOI":"10.3389\/fmed.2021.600121","volume":"8","author":"V Rodriguez-Lara","year":"2021","unstructured":"Rodriguez-Lara V, Avila-Costa MR (2021) An overview of lung cancer in women and the impact of estrogen in lung carcinogenesis and lung cancer treatment. Front Med (Lausanne) 8:600121. https:\/\/doi.org\/10.3389\/fmed.2021.600121","journal-title":"Front Med (Lausanne)"},{"issue":"8","key":"3917_CR35","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1111\/1759-7714.13528","volume":"11","author":"J Xiao","year":"2020","unstructured":"Xiao J, Chen X, Lu X and others (2020) Progesterone\/Org inhibits lung adenocarcinoma cell growth via membrane progesterone receptor alpha. Thorac Cancer 11(8):2209\u20132223. https:\/\/doi.org\/10.1111\/1759-7714.13528","journal-title":"Thorac Cancer"},{"key":"3917_CR36","doi-asserted-by":"publisher","unstructured":"Solairaja S, Venkatabalasubramanian S (2024) Beyond hormones: investigating the impact of progesterone receptor membrane component 1 in lung adenocarcinoma. J Membr Biol 257(3-4):231\u2013243. https:\/\/doi.org\/10.1007\/s00232-024-00311-6","DOI":"10.1007\/s00232-024-00311-6"},{"issue":"5","key":"3917_CR37","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3892\/or.2013.2336","volume":"29","author":"M Xie","year":"2013","unstructured":"Xie M, You S, Chen Q and others (2013) Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor \u03b1-mediated mechanisms. Oncol Rep 29(5):1873\u20131880. https:\/\/doi.org\/10.3892\/or.2013.2336","journal-title":"Oncol Rep"},{"issue":"3","key":"3917_CR38","doi-asserted-by":"publisher","first-page":"951","DOI":"10.21873\/anticanres.16240","volume":"43","author":"JH Check","year":"2023","unstructured":"Check JH, Poretta T, Check D and others (2023) Lung cancer - standard therapy and the use of a novel, highly effective, well tolerated, treatment with progesterone receptor modulators. Anticancer Res 43(3):951\u2013965. https:\/\/doi.org\/10.21873\/anticanres.16240","journal-title":"Anticancer Res"},{"issue":"8","key":"3917_CR39","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1080\/10428190701471999","volume":"48","author":"MD Srivastava","year":"2007","unstructured":"Srivastava MD, Thomas A, Srivastava BI and others (2007) Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone. Leuk Lymphoma 48(8):1610\u20131617. https:\/\/doi.org\/10.1080\/10428190701471999","journal-title":"Leuk Lymphoma"},{"key":"3917_CR40","doi-asserted-by":"publisher","unstructured":"Cohen R, Check JH, DiAntonio A et al (2012) Progesterone induced blocking factor (PIBF), an immunosuppressive protein that inhibits natural killer (NK) cell cytolytic activity, detected 3 days after embryo transfer (ET). Fertil Steril 98(3). https:\/\/doi.org\/10.1016\/j.fertnstert.2012.07.105","DOI":"10.1016\/j.fertnstert.2012.07.105"},{"issue":"2","key":"3917_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1600-0897.1999.tb00468.x","volume":"42","author":"Z Faust","year":"1999","unstructured":"Faust Z, Laskarin G, Rukavina D and others (1999) Progesterone-induced blocking factor inhibits degranulation of natural killer cells. Am J Reprod Immunol 42(2):71\u201375. https:\/\/doi.org\/10.1111\/j.1600-0897.1999.tb00468.x","journal-title":"Am J Reprod Immunol"},{"issue":"3","key":"3917_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1054\/mehy.2001.1333","volume":"57","author":"JH Check","year":"2001","unstructured":"Check JH, Nazari P, Goldberg J et al (2001) A model for potential tumor immunotherapy based on knowledge of immune mechanisms responsible for spontaneous abortion. Med Hypotheses 57(3):337\u2013343. https:\/\/doi.org\/10.1054\/mehy.2001.1333","journal-title":"Med Hypotheses"},{"key":"3917_CR43","doi-asserted-by":"publisher","unstructured":"Chlebowski RT, Schwartz AG, Wakelee H et al (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 374(9697):1243\u20131251. https:\/\/doi.org\/10.1016\/S0140-6736(09)61526-9","DOI":"10.1016\/S0140-6736(09)61526-9"},{"key":"3917_CR44","doi-asserted-by":"publisher","unstructured":"Lother SA, Harding GA, Musto G et al (2013) Antiestrogen use and survival of women with non-small cell lung cancer in Manitoba, Canada. Hormones & cancer 4(5):270\u2013276. https:\/\/doi.org\/10.1007\/s12672-013-0149-7","DOI":"10.1007\/s12672-013-0149-7"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03917-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-025-03917-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-025-03917-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T16:02:19Z","timestamp":1752940939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-025-03917-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3917"],"URL":"https:\/\/doi.org\/10.1007\/s11845-025-03917-4","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Committee of N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russian Federation. All patients provided written informed consent under the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}